TRILIO
17.5.2022 13:08:04 CEST | Business Wire | Press release
KUBECON + CLOUDNATIVECON EUROPE— Trilio , a leading provider of cloud-native data protection, today announced a technical preview of a new “Continuous Restore” capability that is being showcased to the cloud-native community at the KubeCon + CloudNativeCon Europe conference. Continuous Restore offers faster levels of replication, restoration and migration of data and metadata from any storage or cloud platform to another, dramatically improving recovery times for cloud-native applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220517005514/en/
Entirely storage-, cloud- and distribution-agnostic, Trilio’s “Continuous Restore” capability will enable users to continuously stage data at multiple and heterogeneous clouds. This means that applications—regardless of where they reside—will be able to tap into that data and be brought online in seconds, achieving exceptional levels of Recovery Time Objectives (RTO). The capability will be introduced as part of the TrilioVault for Kubernetes cloud-native data protection and management platform.
“Distributed environments consisting of core, edge and cloud resources are becoming the predominant architecture for enterprises today,” said Murali Balcha, Founder and CTO of Trilio. “Companies frequently need to move stateful applications and their data volumes among these diverse environments to achieve cost-efficiency, performance, security and disaster recovery imperatives. Unfortunately, no easy-to-use, affordable solution for continuous data volume replication across heterogeneous infrastructure environments exists today.”
“Trilio’s Continuous Restore capability enables migration and replication of stateful applications in seconds or minutes so that all companies can protect and use their data anywhere—regardless of what the application runs on or where the data is stored,” continued Balcha. “This provides organizations the ability to meet leading levels of application uptime, achieve Service Level Agreements (SLAs) expected of production-grade applications—all at an affordable cost. Continuous Restore is a game-changer that will make today’s modern businesses even more competitive and resilient.”
***To see a Demo of Continuous Restore, visit Trilio at Booth P11 at KubeCon + CloudNativeCon Europe or schedule a meeting with our K8s Experts ***
Use cases for the Continuous Restore capability include:
1. Disaster Recovery: Users will be able to achieve availability objectives and recover from outages or failures in a matter of seconds or minutes rather than days or weeks. Using Continuous Restore, Recovery Time Objectives (RTO) will improve by over 80% versus traditional methods.
2. Application Migrations : Continuous Restore allows IT teams to optimize performance and achieve better Total Cost of Ownership (TCO) by choosing the infrastructure best suited to current needs. The Continuous Restore capability will also enable organizations to unify their infrastructure, especially those that have grown quickly and adopted a variety of compute platforms and storage solutions to meet unique needs. Continuous Restore will make possible tremendously fast application mobility across infrastructure silos, making them silos no more.
3. Testing/Development: Developers can increase the velocity of CI/CD pipelines by staging data for multiple test/dev environments. These test/dev environments can be spun up in seconds with continuously replicated production data and accelerating the push of validated changes into production. In fact, DevOps teams can use this capability to test their “restore” protocols to ensure that restore will work when needed.
4. Data Curation from Edge Clouds: As distributed environments proliferate in the future, massive amounts of data will be collected at “the edge,” and this information from diverse architectures will need to be rapidly replicated and moved throughout distributed systems where it can be assimilated and centrally analyzed by any number of different applications.
Attend Trilio’s Session: “ Cloud-Native App Recoverability & Portability in a Matter of Seconds thru the Unification of Information Silos'' on Thursday May 19 3pm CET at the Microsoft Azure Booth P12. Join Ben Morrison, solution architect at Trilio, for his presentation and demo showcasing Trilio's capability for migrating a stateful application from on-prem Red Hat OpenShift to Azure AKS in a matter of seconds — highlighting the flexibility and speed enabled by the TrilioVault for Kubernetes platform.
Continuous Restore is a capability within TrilioVault for Kubernetes and will be made generally available as part of a product release in Q3’22. For those that want to preview or test the capability, please contact Trilio .
About Trilio
Trilio is a leader in cloud-native data protection for Kubernetes, OpenStack and Red Hat Virtualization environments. Our TrilioVault technology is trusted by cloud infrastructure operators and developers for backup and recovery, migration and application mobility. Customers in telecom, defense, automotive and financial services leverage TrilioVault to recover from disasters, migrate workloads, move workloads to new infrastructure and migrate to new software distributions. Trilio.io , Twitter and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220517005514/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom